Faculty & Staff

Ryan A Schneider, Pharm.D., Ph.D
Ryan A Schneider, Pharm.D., Ph.D
Associate Professor & Associate Dean for Operations and Effectiveness
Year started at UF: 2011
Contact Information
Office Location: 300 Davis Street 145 B
Telephone: 419-434-5410
Credentials
Pharm.D., Ohio Northern University
Ph.D, The Ohio State University
  • Academic Credentials:

    Doctor of Philosophy in Pharmacy (Pharmacology), The Ohio State University
    Doctor of Pharmacy in Pharmacy, Ohio Northern University

    Additional Credentials:
    Licensed Pharmacist, State of Ohio

    Certifications:
    Train-the-trainer for American Pharmacists Association, Pharmacy-Based Immunization Delivery Training Program, 2016

    American Pharmacists Association, The Pharmacist & Patient-Centered Diabetes Care Certificate Training Program, 2015

    American Heart Association, Basic Life Support Instructor, 2012-Present

    American Heart Association, Basic Life Support for Healthcare Provider (CPR & AED)​, 2011-Present

    American Heart Association, Advanced Cardiac Life Support Instructor. 2011-Present

    American Heart Association, Advanced Cardiac Life Support Provider, 2011-Present 

    American Pharmacists Association, Pharmacy-Based Immunization Delivery Training Program, 2010

    American Pharmacists Association, Medication Therapy Management Certificate Training Program, 2009

    Biography:
    Following graduation from Ohio Northern University with a Pharm.D., Dr. Schneider attended graduate school at The Ohio State University to pursue a Ph.D. in Pharmacology.  While a graduate student, Dr. Schneider's research emphasis focused on the role of PIN1 (Peptidylprolyl Cis/Trans Isomerase, NIMA-Interacting 1) and synthetic disintegrins on tumor growth and progression.  He also taught several pharmacology lectures to Pharm.D. students and served as a teaching assistant for pharmacology laboratories for undergraduate BSPS students.  

    Upon completion of his Ph.D., Dr. Schneider followed his passions for teaching and research and joined the faculty at The University of Findlay, College of Pharmacy in 2011 and is currently an Associate Professor of Pharmaceutical Sciences.  He teaches in several pathophysiology, pharmacology and therapeutics disease state courses offered to fourth and fifth year pharmacy students and co-coordinates the endocrinology and metabolism course.  In addition to his efforts in the classroom, Dr. Schneider currently serves as chair of the Department of Pharmaceutical Sciences.

    Dr. Schneider maintains an active research laboratory and mentors several undergraduate and graduate pharmacy students.  He collaborates with Dr. David Kinder, a medicinal chemist at Ohio Northern University, on projects related anti-cancer drug development related to sigma receptors.  He also collaborates with Dr. Rahul Khupse and Dr. Richard Dudley, both medicinal chemists at The University of Findlay, College of Pharmacy, to investigate anti-cancer properties of novel chalcone and bisphenol derivatives.  

    Dr. Schneider has a passion for pharmacy advocacy and currently contributes in this regard as President of the Ohio Pharmacists Association.  To stay current with contemporary pharmacy practices, Dr. Schneider maintains an active community pharmacy practice with Pharmacy Solutions/Riley Creek Pharmacy in Pandora, OH.​​   
  • ​Professional Affiliations:

    American Society for Pharmacology and Experimental Therapeutics, 2006-Present

    American Pharmacists Association, 2011-Present

    American Association of Colleges of Pharmacy, 2011-Present

    Ohio Pharmacists Association, 2005-Present 

    Kappa Psi Pharmaceutical Fraternity, 2003-Present​ 

    Professional Service:

    National:
    American Pharmacists Association - Ohio Delegate, House of Delegates, APhA Annual Meeting, Nashville, TN

    American Association of Colleges of Pharmacy Faculty Delegate, House of Delegates, AACP Annual Meeting, National Harbor, MD, 2015

    American Association of Colleges of Pharmacy Faculty Delegate, House of Delegates, AACP Annual Meeting, Grapevine, TX, 2014

    American Society for Pharmacology & Experimental Therapeutics – Tagline & Logo Taskforce, 2013

    American Pharmacists Association - Academy of Pharmaceutical Research and Science Delegate, House of Delegates,  APhA Annual Meeting, New Orleans, LA, 2012

    American Pharmacists Association  – Academy of Pharmaceutical Research and Science Awards Committee, 2011

    State:
    Ohio Pharmacists Association, President and Executive Committee Member, 2018-Present

    Ohio Pharmacists Association, President-Elect and Executive Committee Member, 2017-2018

    Ohio Pharmacists Association, Vice President and Executive Committee Member, 2016-2017

    Ohio Pharmacists Association, Finance Committee, 2016-Present

    Ohio Pharmacists Association, Public and Professional Relations Committee, 2013-Present

    Ohio Pharmacists Association, Legal and Regulatory Affairs Committee, 2011-Present

    Ohio Pharmacists Association, Practice Advancement and Innovation Committee (formerly the Disease State Management/Medication Therapy Management Task Force Committee), 2011-Present


  • ​Peer-Reviewed Publications:

    Liu T*, Schneider RA*, Lee NY, Hoyt DG. Peptidylprolyl cis/trans isomerase, NIMA-interacting 1 (PIN1) regulates pulmonary effects of endotoxin and tumor necrosis factor-α in mice. Biochem Biophys Res Commun. 2014 Sep 26; 452(3):468-72. * Denotes that these authors contributed equally to this work.

    Dudley RW, Harsayne J, Schneider RA, Edelbrock MA. Effect of vancomycin on HEI-OC1 cells at clinical and supra-therapeutic concentrations. Journal of Pharmaceutical Research and Opinion. 2013; 3(1): 1-4.

    Liu T, Schneider RA, Hoyt DG. Calpastatin is regulated by protein never in mitosis gene A interactive-1 (PIN1) in endothelial cells. Biochem Biophys Res Commun. 2011 Oct 28;414(3):581-6.

    Liu T, Schneider RA, Shah V, Huang Y, Likhotvorik RI, Keshvara L, Hoyt DG. Protein Never in Mitosis Gene A Interacting-1 regulates calpain activity and the degradation of cyclooxygenase-2 in endothelial cells. J Inflamm (Lond). 2009 Jun 22;6:20.

    Selected Abstracts and Poster Presentations:

    Mosler CR, Schneider RA, Dudley RW. “You Decide": An elective course designed using student-selected topics. Poster session presented at: American Association of Colleges of Pharmacy Annual Meeting; 2018; Boston, MA.

    ​Guy JW, Ernsthausen LJ, Schneider RA, Dudley RW. Integrating the instruction of medicinal chemistry and pharmacology to improve student learning and inform therapeutics. Poster session presented at: American Association of Colleges of Pharmacy Annual Meeting; 2018; Boston, MA.

    Stang CRT, Inbody, LR, Stitzlein LM, Dick MJ, Eichel AM, Orahood CB, Mohamed AH, Dudley RW, Schneider RA. Structure-activity analysis of bisphenol-Z derivatives for anticancer activity. FASEB J, 32: no 1 supplement: 836.10. 2018. 

    Inbody LR, Stang CRT, Eichel AM, Orahood CB, Dick MJ, Mohamed AH, Hickey MC, Khupse RS, Schneider RA. Investigation of non-caspase mediated mechanisms of death in response to treatment with novel chalcone in glioblastoma cell lines. FASEB J, 32: no 1 supplement: 566.1. 2018.

    Stang CRT, Inbody LR, Orahood CB, Dick MJ, Eichel AM, Mohamed AH, Faler AD, Zaibek AE, Kinder DH, Schneider RA. Structure-activity relationship of novel compounds based on tamoxifen with proposed Sigma-2 receptor activity. FASEB J, 32: no 1 supplement: 836.5. 2018. (Presented as a poster and also as a 5-minute Datablitz podium presentation)

    Faler AD, Stang CRT, Khupse RS, Schneider RA. Screening of a small flavonoid library for anti-cancer activity against glioblastoma. FASEB J. 31: no 1 Supplement: 823.4. 2017.

    Stang CRT, Adams BR, Faler AD, Schuler BR, Eichel AM, Dick MJ, Orahood CB, Whited TL, Rao PSS, Dudley RW, Khupse RS, Schneider RA. Induction of apoptosis and generation of reactive oxygen species by novel chalcone derivatives. FASEB J. 31: no 1 Supplement: 670.10. 2017.

    Stang CRT, Adams BR, Faler AD, Schuler BR, Kinder DH, Sabol P, Carlston L, Schneider RA. Modulation of autophagy proteins in response to a compound designed as a Sigma-2 receptor agonist derived from tamoxifen. FASEB J. 31: no 1 Supplement: 670.4. 2017.

    Milks MM, Schneider RA, Shinn B, Earle SB, Ternullo S, Khupse RS, Ernsthausen L, Malone PM, Parker DL. Rescue, Remediation, and Retention: The 3 R's of Pharmacy Student Success. Am J Pharm Educ 2016; 80 (5) Article S2. 

    Whited TL, Stang CRT, Adams BR, Khupse RS, Dudley RW, Schneider RA. Optimization of a series of novel chalcone derivatives for anti-cancer activity. FASEB J. 30: no. 1 Supplement:515.3. 2016. (Podium Presentation)

    Adams BR, Stang CRT, Carlston L, Faler AD, Thomas CD, Schuler BR, Eichel AM, Whited TL, Kinder DH, Schneider RA. Anti-cancer effects of a proposed Sigma-2 receptor agonist structurally similar to tamoxifen. FASEB J. 30: no. 1 Supplement:937.8. 2016.

    Schneider RA, Whited TL, Adams BR, Miller IT, Stang CRT, Kim LY, Dudley RW, Kinder DH. Modulation of COX-1 and COX-2 protein levels by selective and non-selective NSAIDs. FASEB J. 29:926.13. 2015.

    Whited TL, Adams BR, Stang CRT, Pierson TJ, Khupse RS, Dudley RW, Schneider RA. Novel Chalcone derivatives show anti-cancer effects in several human cancer cell lines. FASEB J. 29:926.15. 2015.

    Schneider RA, Miller IT, Renz MM, Whited TL, Kim LY, Adams BR, Dudley RW, Kinder DH.  COX-2 is induced by the COX-2 selective inhibitors celecoxib and etodolac and the non-selective inhibitor ibuprofen in several human tumor cell lines. FASEB J. 28:397.8. 2014. (Podium Presentation)

    Schneider RA, Reiff LN, Dudley RW. Induction of apoptosis in MCF-7 and NCI/ADR-RES cells by triazole-containing estradiol analogs. FASEB J. 27:1105.18. 2013.

    Schneider RA, Eckles KG, Kelty VC, Palmisano LR, Strozewski KA, Teckmeyer JS, Kinder DH. Celecoxib induces apoptosis by the intrinsic pathway in HT-29 colon carcinoma and A375 melanoma cells. FASEB J. 27:1105.10. 2013.

    Schneider RA, Liu T, Hoyt DG.  Calpastatin mediates the effect of PIN1 on calpain activity in murine aortic endothelial cells. FASEB J. 25:820.27. 2011.

    Schneider RA, Liu T, Hoyt DG. Hypoxia differentially affects proliferation and death of Lewis Lung Carcinoma cells containing or lacking PIN1. FASEB J. 25:243.3. 2011. (Podium Presentation)

    Schneider RA, Liu T, Williams LM, Hoyt DG. Depletion of PIN1 in EMT6 mammary carcinoma cells decreases cleavage of caspase-3 and increases hypoxia-induced HIF-1α and VEGF expression and responsiveness to VEGF. FASEB J. 25:792.15. 2011.

    Pharmacy Continuing Education Presentations:

    Schneider RA. New Drug Update 2017. Pharmacy Continuing Education presented at: ThoughtSpot 2017, 2017 Jul 20; Las Vegas, NV. ACPE CE# 0864-9999-17-036-L01-P.​

    Schneider RA. Review of Drug Interaction Considerations. Pharmacy Continuing Education presented at: ThoughtSpot 2016, 2016 Jul 30; Las Vegas, NV. ACPE CE# 0449-0000-16-056-L01-P.

    Schneider RA. New Drug Update 2016. Pharmacey Continuing Education presented at: ThoughtSpot 2016, 2016 Jul 27; Las Vegas, NV. ACPE CE# 0449-0000-16-050-L04-P. 

    Schneider RA. Advances in Targeted Cancer Therapy. Pharmacy Continuing Education presented at: ThoughtSpot 2015, 2015 Jul 30; Las Vegas, NV. 

    ​Browning EC, Mobayed M, Pohlmeyer R, Schneider RA. Unsettled Science of Breast Cancer Care. Pharmacy Continuing Education presented at Grand Rounds, The University of Findlay College of Pharmacy; 2015 Apr 7; Findlay, OH. 

    Schneider RA, Dudley RW. Precepting: Best Practice for Preceptors and Students. (New Drug Update 2014). Pharmacy Continuing Education presented at: Hub-Site Meeting; 2014 Sep 18; Findlay, OH.

    Schneider RA, Dudley RW, Milks MM. Precepting: Focusing on what’s at stake for preceptors and students. (An emphasis on pharmacology and the basic sciences).  Pharmacy Continuing Education presented at: Hub-Site Meeting; 2013 Sep 19; Findlay, OH.

    Schneider RA. Hyperlipidemia Consensus Guidelines and Niacin Controversy. Pharmacy Continuing Education presented at: 134th Ohio Pharmacists Association Annual Conference & Trade Show; 2012 Apr 20; Columbus, OH. 

    Schneider RA. New Drug Update. Pharmacy Continuing Education presented at: Medco Health Solutions; 2012 Feb 2; Fairfield, OH. 

    Schneider RA. Pharmacogenomics: Is Personalized Medicine the Future?. Pharmacy Continuing Education presented at:  Medco Health Solutions; 2011 Dec 11; Las Vegas, NV. ACPE 

    Schneider RA, Pohlmeyer R. Identification, Staging and Treatment of Melanoma. Pharmacy Continuing Education presented at: Grand Rounds, The University of Findlay College of Pharmacy; 2011 Oct 13; Findlay, OH. 

    Schneider RA. An Overview of the Pharmacological Management of Hyperlipidemia. Pharmacy Continuing Education presented at: Medco Health Solutions; 2011 Jun 09; Tampa, FL. 

    Schneider RA. An overview of targeted cancer therapy: a pharmacological and clinical perspective. Pharmacy Continuing Education presented at: 128th Ohio Pharmacists Association Annual Conference & Trade Show; 2006 Apr 23; Columbus, OH.